TPP1 and Seizure: It is estimated that 14,000 people in the world have CLN2.3The global prevalence of CLN2 is 0.6–0.7 per million inhabitants.3In the classic form of CLN2, the first signs and symptoms occur in the early years of life, and children present progressive decline in language, cognitive and motor skills, drug-resistant epileptic seizures, visual loss, and premature death.4The enzyme replacement therapy (ERT) is available in the United States and European Union since 2017 and in Brazil since 2018.5, 6, 7It changes the course of the disease, with less language and motor function decline.8